The Evolving Treatment Landscape of Acid-Related Disorders: The Role of New and Emerging Potassium-Competitive Acid Blocker Therapies (Pharmacist Credit)

Program Description
Across the United States, up to 70 million people are affected by acid-related disorders, including Helicobacter pylori infection, gastroesophageal reflux disease, and its more serious form, erosive esophagitis. Acid-related disorders result in greater health-related quality of life burden for patients, and treatment of these conditions has been limited by antibiotic resistance, adverse effects, treatment regimens, and disease recurrence. The recent approval of a potassium-competitive acid blocker (PCAB) with a differentiated mechanism of action from proton pump inhibitors may overcome these challenges. Pharmacists must understand current practice guideline recommendations for treatment and prevention of complications of acid-related disorders as well as the safety and efficacy data for PCAB therapy and ongoing clinical studies for its use across other digestive diseases. Dosing recommendations, management of potential adverse effects and drug interactions, and counseling points for pharmacists to improve medication adherence and health-related quality of life using PCAB therapy will also be addressed.

Target audience: Health-system, managed care, retail, and specialty pharmacists

Type of activity: Application
Release date: August 1, 2023
Expiration date: August 1, 2024

Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the disease burden and current unmet needs in the treatment landscape of acid-related disorders
• Compare the mechanism of action, safety, and efficacy of new and emerging potassium-competitive acid blockers (PCABs) and strategies for their integration in clinical practice
• Explore the role of pharmacists in optimizing the management of patients with acid-related disorders by ensuring proper use of the novel PCABs and approaches for improving adherence and adverse effect management